Abstract Library

#4013 A phase 3 randomised study of 177Lu-edotreotide or everolimus in patients with advanced neuroendocrine tumors of lung or thymic origin (LEVEL, GETNE-T2217)

Introduction: Retrospective data for peptide receptor radionuclide therapy (PRRT) have demonstrated promising activity in somatostatin receptor (SSTR)-positive lung neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: García-Álvarez A, Garcia-Carbonero R, Anido U, Jimenez-Fonseca P, Del Olmo-García M,

Keywords: Lung NET, Peptide receptor radionuclide therapy,

#3646 Thymic neuroendocrine neoplasms – Data from the Czech Neuroendocrine Tumor Registry 2008 – 2022

Introduction: Thymic neuroendocrine neoplasms are very rare, their incidence is only 3% of all NENs a 5% of thymic tumors. On ENETS 2022 Sarah Fodil—Cherif et alt. presented data of 74 patients with thymic NETs from retrospective French study (1988-2020) and their analysis.

Conference:

Presenting Author:

Authors: Sedlackova E, Barkmanova J, Linke Z, Karpianusova T,

Keywords: thymic neoplasms, neuroendocrine tumor,

#3008 A Single-Center Retrospective Analysis of Thymic Neuroendocrine Tumor

Introduction: Thymic neuroendocrine tumor (NET) is a rare type of tumor located in the anterior mediastinum.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Chen J,

Keywords: thymic neuroendocrine tumor, atypical carcinoid,

#1804 Open-Label Multicentre Single-Arm Phase 2 Trial of Lanreotide Autogel (LAN) in Combination with Temozolomide (TMZ) in Patients with Advanced Well/Moderately Differentiated Neuroendocrine Tumours (NETs) of Lung and Thymus: ATLANT

Introduction: In phase 3 CLARINET study, LAN 120mg every 28 days significantly prolonged progression-free survival (PFS) vs placebo in pts with well-differentiated metastatic enteropancreatic NETs, but limited data exist for somatostatin analogues in advanced lung/thymic NETs. Evidence that TMZ may be active in thoracic NETs is mainly retrospective.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Ferolla P, Berruti A, Fazio N, Mazzanti P, Houchard A,

Keywords: Temozolomide, lanreotide,

#664 Natural Course and Survival of Thymic and Bronchopulmonary Neuroendocrine Tumors are Different for Male and Female MEN-1 Patients

Introduction: The course of thymic- and bronchopulmonary neuroendocrine tumors (Th- and Bp-NET) in MEN-1 patients is still unclear.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: De Laat J, Pieterman C, Twisk J, Hermus A, Dekkers O,

Keywords: MEN-1, lung NET, thymic NET, natural course, survival,